ABOUT OUR TECHNOLOGY
Acuitas specializes in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles (LNP). Acuitas LNP carriers are clinically validated and can be given by various routes of administration. Further, Acuitas has established the mechanism by which our LNP carriers are taken up by cells (Akin et al 2010 DOI:10.1038/mt.2010.85). In collaboration with industry and academic partners, we have shown the potential clinical application of messenger RNA (mRNA)-LNP as vaccines (Pardi et al 2017 DOI:10.1038/nature21428), protein replacement therapeutics (Thess et al 2015 DOI:10.1038/mt.2015.103), gene silencing (Jayamaran et al 2012 DOI:10.1002/anie.201203263) and antibody therapeutics (Pardi et al 2017 DOI:10.1038/ncomms14630). We are also evaluating mRNA-LNP for various gene editing applications. Together, with our partners, we continue to advance and optimize our delivery technology to address unmet clinical needs.